Skip to main content

Developing A NextGen RNA Therapy for Rett Syndrome

December 16, 2020
cure_360_webinar_youtube_thumbnail_-_nextgen_rna_therapy_1500_x_700_px

David Huss, PhD, VP, Head of Research for Shape Therapeutics discusses the company's proprietary RNA technologies and how they will be applied to fix MECP2 mutations, the root cause of Rett syndrome.

Recording

More Resources

Our Plan for a Cure: RNA Editing

Our Plan for a Cure: RNA Trans-Splicing

$40M